ERNA 1200 Stretch.jpg
Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors
February 20, 2024 08:30 ET | Eterna Therapeutics
Eterna Therapeutics (ERNA) Announces the Appointment of Peter Cicala, JD, to its Board of Directors
ERNA 1200 Stretch.jpg
Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)
January 03, 2024 16:15 ET | Eterna Therapeutics
CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell...
ERNA 1200 Stretch.jpg
Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer
December 20, 2023 16:15 ET | Eterna Therapeutics
CAMBRIDGE, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell...
ERNA 1200 Stretch.jpg
Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing
December 14, 2023 18:56 ET | Eterna Therapeutics
CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) --  Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell...
ERNA 1200 Stretch.jpg
Eterna Therapeutics Appoints James Bristol, Ph.D., Pharmaceutical Research and Drug Discovery Veteran, to Board of Directors
November 01, 2023 08:30 ET | Eterna Therapeutics
CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell...
ERNA 1200 Stretch.jpg
Eterna Therapeutics Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Lineage Cell Therapeutics
September 06, 2023 08:00 ET | Eterna Therapeutics
mRNA cell engineering strategically targets genes to create novel and potentially superior product profiles for cell transplant therapy applications Novel engineered iPS cell line to be evaluated by...
Dorothy Clarke
Eterna Therapeutics Appoints Biopharma Industry Veteran Dorothy Clarke to Board of Directors
September 05, 2023 08:30 ET | Eterna Therapeutics
CAMBRIDGE, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell...
ERNA 1200 Stretch.jpg
Eterna Therapeutics Announces Completion of $8.7 Million of Convertible Debt Financing
July 18, 2023 08:00 ET | Eterna Therapeutics
CAMBRIDGE, MASS., July 18, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell...
ERNA 1200 Stretch.jpg
Eterna Therapeutics Appoints Biotech Industry Veterans Brant Binder and Richard Wagner, Ph.D. to Board of Directors
July 11, 2023 08:30 ET | Eterna Therapeutics
CAMBRIDGE, Mass., July 11, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell...
Megan Yung
Eterna Therapeutics Appoints Megan Yung as Chief Strategy Officer, General Counsel
May 24, 2023 08:30 ET | Eterna Therapeutics
CAMBRIDGE, Mass., May 24, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell...